Who are Trastuzumab and Hyaluronidase-oysk's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): NERATINIB, Herceptin, Herceptin, Disitamab Vedotin combined with Tislelizumab, Ado Trastuzumab Emtansine, Disitamab vedotin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/trastuzumab-and-hyaluronidase-oysk.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Trastuzumab and Hyaluronidase-oysk — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trastuzumab and Hyaluronidase-oysk (Trastuzumab and Hyaluronidase-oysk) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Endoglycosidase [EPC].

marketed Endoglycosidase [EPC] HER2 Small molecule Live · refreshed every 30 min

Target snapshot

Trastuzumab and Hyaluronidase-oysk (Trastuzumab and Hyaluronidase-oysk) — Adrienne G. Waks. Trastuzumab inhibits HER2-overexpressing tumor cell proliferation and mediates ADCC, while hyaluronidase increases subcutaneous permeability for better drug absorption.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Trastuzumab and Hyaluronidase-oysk TARGET	Trastuzumab and Hyaluronidase-oysk	Adrienne G. Waks	marketed	Endoglycosidase [EPC]	HER2
NERATINIB	NERATINIB		marketed		EGFR, HER2, HER4	2017-01-01
Herceptin	Trastuzumab-Qyyp	Roche	marketed	HER2/neu receptor antagonist monoclonal antibody	HER2 (c-erbB2) proto-oncogene transmembrane receptor protein	1998-01-01
Herceptin	trastuzumab	Roche	marketed	Antibody-drug conjugate (ADC)	HER2 receptor, subdomain IV	1998-01-01
Disitamab Vedotin combined with Tislelizumab	Disitamab Vedotin combined with Tislelizumab	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	marketed	Antibody-drug conjugate combined with PD-1 inhibitor	HER2 (disitamab vedotin); PD-1 (tislelizumab)
Ado Trastuzumab Emtansine	Ado Trastuzumab Emtansine	Medstar Health Research Institute	marketed	Antibody-drug conjugate (ADC)	HER2 (human epidermal growth factor receptor 2)
Disitamab vedotin	disitamab-vedotin	Pfizer	marketed	antibody-drug conjugate	human epidermal growth factor receptor 2 (HER2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Endoglycosidase [EPC] class)

Adrienne G. Waks · 1 drug in this class
Argenx Bv · 1 drug in this class
Genentech, Inc. · 1 drug in this class
M. Peter Marinkovich · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Trastuzumab and Hyaluronidase-oysk — Competitive Intelligence Brief. https://druglandscape.com/ci/trastuzumab-and-hyaluronidase-oysk. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab